Psoriasis patient source of business for major IL-23 agents
CRA analytics insight A higher proportion of Tremfya patients, versus Skyrizi patients, were previously treated with an IL-17 agent (i.e., Cosentyx or Taltz)...
Travis Ruch
Principal
Travis Ruch is a principal in the Life Sciences Practice at CRA. Dr. Ruch has experiences across commercial strategy with a focus on analytics and development of pipeline assets. He has expertise across a wide variety of therapeutic areas including rare disease, immunology, pulmonary disease, kidney disease, CNS disorders, and metabolic conditions.
Prior to joining CRA Dr. Ruch worked as a research scientist investigating cell biology, infectious disease, and cystic fibrosis.
Credentials
Get In Touch
Travis Ruch